Fate Therapeutics Stock Price, Forecast & Analysis (NASDAQ:FATE)

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics Inc (NASDAQ:FATE) posted its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The biopharmaceutical company earned $2.43 million during the quarter, compared to the consensus estimate of $1.75 million. Fate Therapeutics had a negative return on equity of 48.94% and a negative net margin of 900.24%. The company's revenue for the quarter was up 136.7% on a year-over-year basis. During the same period last year, the firm posted ($0.31) EPS. View Fate Therapeutics' Earnings History.

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Fate Therapeutics.

16 brokers have issued 1-year target prices for Fate Therapeutics' stock. Their forecasts range from $16.00 to $32.00. On average, they expect Fate Therapeutics' share price to reach $24.94 in the next year. This suggests a possible upside of 69.4% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

News articles about FATE stock have been trending positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fate Therapeutics earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include Repligen (RGEN), bluebird bio (BLUE), Spark Therapeutics (ONCE), BioNTech (BNTX), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Denali Therapeutics (DNLI) and Coherus Biosciences (CHRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Neurocrine Biosciences (NBIX), Tandem Diabetes Care (TNDM), Exelixis (EXEL), Amicus Therapeutics (FOLD) and Portola Pharmaceuticals (PTLA).

Fate Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (1.29%), Sumitomo Mitsui Trust Holdings Inc. (1.29%), First Trust Advisors LP (0.28%), California Public Employees Retirement System (0.23%), Alps Advisors Inc. (0.20%) and Lisanti Capital Growth LLC (0.19%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors and Alps Advisors Inc.. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.

FATE stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Lisanti Capital Growth LLC, First Trust Advisors LP, Boston Advisors LLC and Chicago Equity Partners LLC. View Insider Buying and Selling for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $14.72.

Fate Therapeutics has a market capitalization of $1.11 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]